Skip to main content
Sign In

David Ross, PhD

Chair, Department of Pharmaceutical Sciences, Professor of Toxicology

Photo of David Ross

Mailing address:

University of Colorado
Skaggs School of Pharmacy and Pharmaceutical Sciences
Mail Stop C238
12850 E. Montview Blvd. V20-2132A
Aurora, CO 80045

Office Location:

Pharmacy and Pharmaceutical Sciences Building (V20)
Second Floor
Room 2132A

Lab Location:

Pharmacy and Pharmaceutical Sciences Building (V20)
Second Floor
Room 2470A/D



  • Member, University of Colorado Cancer Center

Training and Education:

  • BSc, University of Aston in Birmingham, England (Pharmacy, Honors)
  • PhD, University of Aston in Birmingham, England (Pharmaceutical Chemistry)
  • MRPS, Member of the Royal Pharmaceutical Society 1979- ; DABT, Diplomate of the American Board of Toxicology, 1993

Research Interests:

Quinones, quinone reductases, selective toxicity of antitumor agents, drug development, targeting of antitumor agents, pharmacogenomics. My laboratory is focused on understanding the role of the quinone reductases in physiological systems and the mechanisms underlying the toxicity of quinones. We then apply that knowledge to a number of different projects in antitumor drug development, environmental toxicology, neurodegeneration and cellular signaling.


Molecular toxicology, drug discovery

Some Recent Publications:

  • Quinone-induced protein handling changes: Implications for major protein handling systems in quinone-mediated toxicity. Xiong R, Siegel D, Ross D. Toxicol Appl Pharmacol. 22;280(2):285-295. 2014.
  • Discovery and characterization of small molecules that target the GTPase Ral. Yan C, Liu D, Li L, Wempe MF, Guin S, Khanna M, Meier J, Hoffman B, Owens C, Wysoczynski CL, Nitz MD, Knabe WE, Ahmed M, Brautigan DL, Paschal BM, Schwartz MA, Jones DN, Ross D, Meroueh SO, Theodorescu D. Nature 515(7527):443-7, 2014.
  • Synthesis and Intracellular Redox Cycling of Natural Quinones and Their Analogues and Identification of Indoleamine-2,3-dioxygenase (IDO) as Potential Target for Anticancer Activity.Blunt CE, Torcuk C, Liu Y, Lewis W, Siegel D, Ross D, Moody CJ. Angew Chem Int Ed Engl. 20;54(30):8740-5. 2015,
  • A Novel Hsp90 Inhibitor Activates Compensatory Heat Shock Protein Responses and Autophagy and Alleviates Mutant A53T α-Synuclein Toxicity Xiong R, Zhou W, Siegel D, Kitson RR, Freed CR, Moody CJ, Ross D.Mol Pharmacol. 88(6):1045-54. 2015.
  • Novel RNA-binding activity of NQO1 promotes SERPINA1 mRNA translation. Di Francesco A, Di Germanio C, Panda AC, Huynh P, Peaden R, Navas-Enamorado I, Bastian P, Lehrmann E, Diaz-Ruiz A, Ross D, Siegel D, Martindale JL, Bernier M, Gorospe M, Abdelmohsen K, de Cabo R. Free Radic Biol Med. 99:225-233, 2016.
  • Synthesis of novel Ral inhibitors. An in-vivo and in-vitro study. Yan C, Theodorescu D, Miller B, Kumar A, Kumar V, Ross D, Wempe MF. Synthesis of novel Ral inhibitors. An in-vivo and in-vitro study. Bioorg Med Chem Lett. 26(23):5815-5818, 2016.
  • Redox modulation of NQO1. David Siegel, Donna D. Dehn, Samantha S. Bokatzian, Kevin Quinn, Donald S. Backos, Andrea Di Francesco, Michel Bernier, Nichole Reisdorph, Rafael de Cabo, David Ross. PLoS One,, 2018


  • Functions of NQO1 in cellular protection and CoQ10 metabolism and its potential role as a redox sensitive molecular switch, Ross, D. and Siegel, D., Frontiers Physiology, 8, 1-8, 2017.
  • Quinone Reductases. Ross, D. and Siegel D in Comprehensive Toxicology,.3rd Edition Ed McQueen C.A., Elsevier, 2017.
  • NQO1 in protection against oxidative stress. Ross, D. and Siegel, D. Current Opinion in Toxicology, 7, 67-72, 2018.

Additional Publications